Rakovina Therapeutics Inc.
RKV.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 247.91% | 172.74% | 74.92% | 42.19% | 24.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 161.40% | 98.22% | 49.82% | 22.42% | 2.02% |
| Operating Income | -161.40% | -98.22% | -49.82% | -22.42% | -2.02% |
| Income Before Tax | -150.15% | -94.29% | -53.05% | -29.36% | -11.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -150.15% | -94.29% | -53.05% | -29.36% | -11.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -150.15% | -94.29% | -53.05% | -29.36% | -11.48% |
| EBIT | -161.40% | -98.22% | -49.82% | -22.42% | -2.02% |
| EBITDA | -202.39% | -125.67% | -63.90% | -28.81% | -2.77% |
| EPS Basic | -38.68% | -32.10% | -27.42% | -20.00% | -10.93% |
| Normalized Basic EPS | -38.19% | -31.56% | -26.95% | -20.00% | -10.95% |
| EPS Diluted | -52.63% | -44.58% | -27.33% | -12.05% | -7.69% |
| Normalized Diluted EPS | -38.19% | -31.56% | -26.95% | -20.00% | -10.95% |
| Average Basic Shares Outstanding | 74.60% | 43.55% | 18.37% | 7.55% | 0.43% |
| Average Diluted Shares Outstanding | 74.60% | 43.55% | 18.37% | 7.55% | 0.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |